Related Experiment Video
Updated: Sep 3, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor XIII deficiency: an updated approach to diagnosis and management
1Hematology Unit, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
Factor XIII deficiency (FXIIID) is a rare bleeding disorder that may be congenital or acquired and is associated with significant morbidity, particularly in its congenital form, including intracranial hemorrhage, impaired wound healing, and adverse pregnancy outcomes. Unlike other coagulation factor deficiencies, FXIIID is not detected by routine coagulation screening tests, contributing to delayed diagnosis and underrecognition. This review provides an updated overview of the epidemiology, molecular biology, clinical manifestations, laboratory diagnosis, and management of FXIIID. Particular emphasis is placed on contemporary diagnostic strategies, including the advantages and limitations of functional, antigen, inhibitor, and genetic assays, as well as preanalytical and analytical pitfalls that may affect test interpretation. Special attention is given to acquired FXIIID, emerging diagnostic challenges, and complex clinical scenarios, including pregnancy, neonatal care, surgery, and anticoagulation. Persistent knowledge gaps, including assay standardization and limited evidence supporting current recommendations for managing special scenarios, are also highlighted. Continued international collaboration and prospective data collection are needed to improve diagnosis, refine treatment strategies, and strengthen future evidence-based guidance.
Factor XIII deficiency (FXIIID) is a rare bleeding disorder that may be congenital or acquired and is associated with significant morbidity, particularly in its congenital form, including intracranial hemorrhage, impaired wound healing, and adverse pregnancy outcomes. Unlike other coagulation factor deficiencies, FXIIID is not detected by routine coagulation screening tests, contributing to delayed diagnosis and underrecognition. This review provides an updated overview of the epidemiology, molecular biology, clinical manifestations, laboratory diagnosis, and management of FXIIID. Particular emphasis is placed on contemporary diagnostic strategies, including the advantages and limitations of functional, antigen, inhibitor, and genetic assays, as well as preanalytical and analytical pitfalls that may affect test interpretation. Special attention is given to acquired FXIIID, emerging diagnostic challenges, and complex clinical scenarios, including pregnancy, neonatal care, surgery, and anticoagulation. Persistent knowledge gaps, including assay standardization and limited evidence supporting current recommendations for managing special scenarios, are also highlighted. Continued international collaboration and prospective data collection are needed to improve diagnosis, refine treatment strategies, and strengthen future evidence-based guidance.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Mitral Stenosis III: Medical Management

